ILLUMINA INC (ILMN)       205.98  -7.88 (-3.68%)

205.98  -7.88 (-3.68%)

US4523271090 - Common Stock - After market: 206.35 +0.37 (+0.18%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ILMN. ILMN was compared to 64 industry peers in the Life Sciences Tools & Services industry. The financial health of ILMN is medium. Also its profitability is quite bad. While showing a medium growth rate, ILMN is valued expensive at the moment.




Profitability

Profitability Rating

1

ILMN has a Piotroski-F score of 4.00. This indicates an average health and profitability for ILMN.
ILMN has negative profitability rations, so we won't be analyzing them here.

ILMN's Return On Assets of -36.90% is worse than the rest of the industry. The industry average Return On Assets is -13.25%.
ILMN has a Profit Margin of -88.38%. This is below the industry average of -29.71%.
VS Industry

ROA (-36.9%) VS Industry: 22% outperformed.

-620.54
57.39

Profit Margin (-88.38%) VS Industry: 34% outperformed.

-91,548.81
383.95

Valuation

Valuation Rating

0

With a price book ratio of 4.81, ILMN is valued correctly.
With a Price/Earnings Ratio of 75.45, ILMN can be considered very expensive at the moment.
With a Price/Earning Ratio of 75.45, ILMN is valued a higher than the industry average, which is at 26.58. 93% of the companies listed in the same industry are cheaper than ILMN!
The Forward Price/Earnings Ratio of 53.87 indicates a quite expensive current valuation of ILMN.

The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
Compared to an average industry price book ratio of 2.38, ILMN is valued more expensive than its industry peers.
Compared to an average industry Enterprise Value to EBITDA ratio of 15.37, ILMN is valued more expensive than its industry peers. 90% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (75.45) VS Industry: 7% outperformed.

112.67
6.58

Price/Book (4.81) VS Industry: 23% outperformed.

52.06
0.22

Enterprise Value/ EBITDA (39.94) VS Industry: 10% outperformed.

723.26
0.30

Growth

Growth Rating

4

ILMN shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 11.95% yearly.
The Revenue has been growing by 13.54% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, ILMN will show a small growth in Earnings Per Share. The EPS will grow by 8.52% on average per year.
Looking at the last year, ILMN shows a small growth in Revenue. The Revenue has grown by 9.79% in the last year.

ILMN is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 8.65% yearly.
ILMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -57.54%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS11.95% 1.38% -57.54% -52.47% -19.9% -5.12% 8.52%
Revenue13.54% 10.74% 9.79% 5.93% 9.05% 11.49% 8.65%

Health

Health Rating

4

An Altman-Z score of 5.27 indicates that ILMN is not in any danger for bankruptcy at the moment.
The Altman-Z score of ILMN is much better than the industry average of 2.29.
The Debt to Equity ratio of ILMN is in line with the industry averages.
The Piotroski-F score of ILMN is 4.00. This is a neutral score and indicates average health and profitability for ILMN.

A Current Ratio of 0.93 indicates that ILMN may have some problems paying its short term obligations.
Compared to an average industry Current Ratio of 4.94, ILMN is worse placed to pay its short term obligations than its industry peers. 96% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.72 indicates that ILMN may have some problems paying its short term obligations.
When comparing the Quick Ratio of ILMN to the average industry Current Ratio of 4.34, ILMN is less able to pay its short term obligations than its industry peers. 97% of its industry peers have a better Quick Ratio.
VS Industry

Debt/Equity (0.07) VS Industry: 53% outperformed.

3.88
0.00

Quick Ratio (0.72) VS Industry: 3% outperformed.

0.23
40.60

Current Ratio (0.93) VS Industry: 4% outperformed.

0.23
40.60

Altman-Z (5.27) VS Industry: 68% outperformed.

-119.81
29.33

Dividend

Dividend Rating

0

No dividends for ILMN!.

ILMN Daily chart

ILLUMINA INC205.98

NASDAQ:ILMN (12/6/2022, 7:00:03 PM)-7.88 (-3.68%)

After market: 206.35 +0.37 (+0.18%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-08 2023-02-08
Ins Owners 0.15% Inst Owners 187.88%
Market Cap 32.40B Analysts 71.2
Valuation
PE 75.45 Fwd PE 53.87
PEG (NY) N/A PEG (5Y) 6.32
P/S 6.9 P/B 4.81
EV/EBITDA 39.94
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -57.54% EPS 3Y 1.38%
EPS 5Y 11.95% EPS growth Q2Q -76.55%
EPS Next Y -52.47% EPS Next 2Y -19.9%
EPS Next 3Y -5.12% EPS Next 5Y 8.52%
Revenue growth 1Y 9.79% Revenue growth 3Y 10.74%
Revenue growth 5Y 13.54% Revenue growth Q2Q 0.63%
Revenue Next Year 5.93% Revenue Next 2Y 9.05%
Revenue Next 3Y 11.49% Revenue Next 5Y 8.65%
Health
Current Ratio 0.93 Quick Ratio 0.72
Altman-Z 5.27 F-Score 4
Debt/Equity 0.07 WACC 9.6%
ROIC/WACC 4.37
Profitability
ROA -36.9% ROE N/A
ROICexgc 41.92% ROIC 4.75%
PM -88.38% OM 10.66%
Asset Turnover 0.42

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA